Table 1 Demographics and clinicopathologic characteristics of the training and validation sets
From: Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer
Variables | Total | Training set | Validation set | P-value |
|---|---|---|---|---|
|  | N = 3398 | N = 2379 | N = 1019 |  |
Age (mean (SD)) | 64.028 (10.307) | 64.055 (10.211) | 63.966 (10.533) | 0.817 |
Sex | Â | Â | Â | Â |
 Female | 1024 (30.14) | 709 (29.80) | 315 (30.91) | 0.545 |
 Male | 2374 (69.86) | 1670 (70.20) | 704 (69.09) |  |
KPS (mean (SD)) | 76.758 (11.01) | 76.598 (11.38) | 77.130 (10.07) | 0.197 |
Stage of cancer | Â | Â | Â | Â |
 I–II | 424 (12.48) | 306 (12.86) | 118 (11.58) | 0.582 |
 III | 749 (22.04) | 523 (21.98) | 226 (22.18) |  |
 IV | 2225 (65.48) | 1550 (65.15) | 675 (66.24) |  |
Pathological type | Â | Â | Â | Â |
 NSCLC | 2973 (87.49) | 2081 (87.47) | 892 (87.54) | 1 |
 SCLC | 425 (12.51) | 298 (12.53) | 127 (12.46) |  |
A history of VTE | Â | Â | Â | Â |
 No | 3226 (94.94) | 2254 (94.75) | 972 (95.39) | 0.486 |
 Yes | 172 (5.06) | 125 (5.25) | 47 (4.61) |  |
Varicosity | Â | Â | Â | Â |
 No | 3377 (99.38) | 2366 (99.45) | 1011 (99.21) | 0.566 |
 Yes | 21 (0.62) | 13 (0.55) | 8 (0.79) |  |
COPD | Â | Â | Â | Â |
 No | 2732 (80.40) | 1906 (80.12) | 826 (81.06) | 0.557 |
 Yes | 666 (19.60) | 473 (19.88) | 193 (18.94) |  |
CVC | Â | Â | Â | Â |
 No | 3288 (96.76) | 2307 (96.97) | 981 (96.27) | 0.340 |
 Yes | 110 (3.24) | 72 (3.03) | 38 (3.73) |  |
History of malignant tumor | Â | Â | Â | |
 No | 3349 (98.56) | 2345 (98.57) | 1004 (98.53) | 1 |
 Yes | 49 (1.44) | 34 (1.43) | 15 (1.47) |  |
BMI | Â | Â | Â | Â |
 < 18.5 | 296 (8.71) | 209 (8.79) | 87 (8.54) | 0.942 |
 18.5–23.9 | 1870 (55.03) | 1305 (54.85) | 565 (55.45) |  |
 ≥ 24 | 1232 (36.26) | 865 (36.36) | 367 (36.02) |  |
PLT (mean (SD)) | 222.456 (99.741) | 222.434 (99.599) | 222.509 (100.121) | 0.984 |
Albumin (mean (SD)) | 38.844 (6.249) | 38.746 (6.318) | 39.071 (6.083) | 0.166 |
D.dimer (mean (SD)) | 2.081 (3.641) | 2.073 (3.676) | 2.099 (3.558) | 0.848 |
PT (mean (SD)) | 11.978 (1.925) | 11.966 (1.800) | 12.005 (2.190) | 0.587 |
APTT (mean (SD)) | 28.438 (5.515) | 28.563 (5.763) | 28.146 (4.877) | 0.044 |
Hemoglobin (mean (SD)) | 121.793 (20.515) | 121.877 (20.666) | 121.597 (20.166) | 0.716 |
Leukocyte (mean (SD)) | 5.541 (5.344) | 5.624 (5.342) | 5.349 (5.345) | 0.169 |
Creatinine (mean (SD)) | 66.794 (37.724) | 66.658 (36.201) | 67.112 (41.076) | 0.748 |
Mitomycin | Â | Â | Â | Â |
 No | 3390 (99.76) | 2374 (99.79) | 1016 (99.71) | 0.938 |
 Yes | 8 (0.24) | 5 (0.21) | 3 (0.29) |  |
rh-Endostatin | Â | Â | Â | Â |
 No | 3290 (96.82) | 2309 (97.06) | 981 (96.27) | 0.275 |
 Yes | 108 (3.18) | 70 (2.94) | 38 (3.73) |  |
EGFR.TKI | Â | Â | Â | Â |
 No | 2995 (88.14) | 2089 (87.81) | 906 (88.91) | 0.395 |
 Yes | 403 (11.86) | 290 (12.19) | 113 (11.09) |  |
Dexamethasone | Â | Â | Â | Â |
 No | 882 (25.96) | 619 (26.02) | 263 (25.81) | 0.932 |
 Yes | 2516 (74.04) | 1760 (73.98) | 756 (74.19) |  |
Platinum | Â | Â | Â | Â |
 No | 2751 (80.96) | 1929 (81.08) | 822 (80.67) | 0.813 |
 Yes | 647 (19.04) | 450 (18.92) | 197 (19.33) |  |
Bevacizumab | Â | Â | Â | Â |
 No | 3320 (97.70) | 2322 (97.60) | 998 (97.94) | 0.636 |
 Yes | 78 (2.30) | 57 (2.40) | 21 (2.06) |  |